Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Solid Tumors

In brief

To evaluate the safety and tolerability of escalating doses of MM-121 + certain anticancer therapies

Key facts

Study ID

NCT01447225

Run by

Merrimack Pharmaceuticals

People needed

43

Starts

2011-10-01

Expected to finish

2014-01-01

Last updated by the study team

2016-09-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced-stage solid tumors
• ≥ 18 years of age
• Adequate liver and kidney function

You may not qualify if…

• Any other active malignancy
• No known HIV, Hepatitis C or B

Where it is running

• Study site — Lafayette, Indiana, United States
• Study site — Buffalo, New York, United States
• Study site — Cincinnati, Ohio, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Villejuif, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.